In a major genetic study, over 5,000 variants linked to increased cancer risk were identified in the BAP1 gene, revealing the potential for new targeted therapies and improving genetic testing for diverse populations.
Researchers have pinpointed specific variants in a gene that significantly raise the likelihood of developing various cancer types. This discovery has the potential to enhance early detection and facilitate personalized treatments for diverse populations.
Scientists have identified over 5,000 genetic variants that help certain cancers thrive, as well as a potential therapeutic target that could treat or possibly prevent these cancers from developing.
Researchers from the Wellcome Sanger Institute, and their collaborators at The Institute of Cancer Research, London, and the University of Cambridge assessed the health impact of all possible genetic changes in the ‘tumour protection’ gene, BAP1. They found around a fifth of these possible changes were pathogenic, significantly increasing the risk of developing cancers of the eye, lung lining, brain, skin, and kidney.
The findings, published in Nature Genetics, are freely available so that they can be immediately used by doctors to help diagnose patients and choose the most effective therapies for them. Importantly, as all possible variants were assessed, the findings benefit individuals from diverse ethnic backgrounds, who have historically been underrepresented in genetics research.
Potential for New Cancer Therapies
The team also uncovered a link between certain disruptive BAP1 variants and higher levels of IGF-1, a hormone and growth factor. This discovery opens the door to developing new drugs that could inhibit these harmful effects, potentially slowing down or preventing the progression of certain cancers.
The BAP1 protein acts as a powerful tumor suppressor in the body, protecting against cancers of the eye, lung lining, brain, skin, and kidney. Inherited variants that disrupt the protein can increase a person’s lifetime risk of developing these cancers by up to 50 per cent, typically occurring around middle age.
Detecting these variants early through genetic screening can guide preventative measures, greatly enhance treatment effectiveness, and improve the quality of life for individuals affected. However, until now, there has been limited understanding of which specific genetic changes in BAP1 to look out for, especially for rare variants that cause it to malfunction and fuel cancer growth.
Researchers from the Sanger Institute, and their collaborators at The Institute of Cancer Research and the University of Cambridge tested all 18,108 possible DOI: 10.1038/s41588-024-01799-3
The study was funded by the Wellcome Trust and Cancer Research UK.



















Discussion about this post